<DOC>
	<DOC>NCT01896336</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of sublingual zolpidem presentation 5 mg in the induction of sleep in patients with primary insomnia.</brief_summary>
	<brief_title>Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia</brief_title>
	<detailed_description>- National study, phase IV, single-center, double-blind, randomized, parallel, controlled by zolpidem 10mg oral. - Experiment duration: 93 days. - 05 visits (days -3, 0, 15, 45 and 90). - Efficacy will be evaluated for: Sleep induction and the maintenance of sleep. - Adverse events evaluation.</detailed_description>
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Men or women aged between 20 and 64 years; Diagnosis of primary insomnia according to criteria defined by DSMIV; Difficulty in maintaining sleep and waking up until 3 am; Not having used any psychoactive drug in the last 30 days prior to their inclusion in the study; Signature of IC. Previous history of serious medical illness, neurological or psychiatric disorder; Allergy or hypersensitivity to zolpidem; Obstructive Sleep Apnea syndrome; Polysomnography with apnea and hypopnea index &gt;10/hour or PLM &gt;15/h; Other secondary sleep disorders; History of substance abuse or dependence; History of daily consumption of alcoholic beverages; Pregnancy, lactation or refusal to use safe contraceptive methods during the study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>